Eckert & Ziegler invests in capacity expansion for its GalliaPharm® production line(PresseBox) ( Berlin, )
“The capacity expansion is part of a more broadly based investment program. We are not only enhancing our production capacity but also focusing particularly on ensuring availability of the currently limited active substance. This way, supply of diagnostic agents for patients and the increasing number of clinical trials using Ga-68-based tracers is guaranteed. In addition, we are expanding our capacities to take back expired generators and transfer them towards duly disposal procedures”, explained Dr. André Heß, Executive Board member at Eckert & Ziegler AG with responsibility for the Radiopharma segment.
The investment is linked to a strengthened strategic focus on theranostic applications. The related products, primarily based on Gallium-68, Yttrium-90 and Lutetium-177 are used for diagnostic and therapeutic purposes of various conditions. Intensifying development of radiopharmaceutical formulations, test batch production of radiopharmaceuticals for clinical trials and initiating cooperation with young, aspiring pharmaceutical companies are additional intentions in the near future.